Precision Medicine

Expert hematologist-oncologists share insight on the evolving role of XPO1 inhibitor therapy in the management of multiple myeloma and myelofibrosis.

Mark Socinski, MD, and Joshua Sabari, MD, discuss the treatment options for patients with KRASG12C mutated NSCLC with CNS metastases, and share advice for community oncologists treating this population.

Two expert hematologist-oncologists review treatment options for patients with follicular lymphoma and consider how to select the appropriate therapy based on patient and disease factors.

Expert hematologist-oncologists review treatment options for patients with myeloproliferative neoplasms and consider patient and disease factors that inform the selection of optimal therapy.

Hetty Carraway, MD, and Eytan M. Stein, MD, discuss treatment options for patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia, and how to select the best treatment regimen based on patient and disease factors.

Expert hematologist/oncologists highlight recent advances in the treatment of advanced RCC and consider their impact on clinical practice.

Hetty Carraway, MD, and Eytan Stein, MD, discuss the frontline treatment options for patients with AML and how to select the best treatment approach based on patient and disease factors.

Shaji Kumar, MD, and Jonathan Kaufman, MD, discuss the role of BCL-2 proteins in multiple myeloma treatment and recent safety and efficacy data on BCL-2 inhibitors.

Two leading experts in lung cancer provide insights on therapies targeting ALK mutations patients with non-small-cell lung cancer.

Reactions to recent data on the integration of CD19-targeted therapies into the treatment of patients with diffuse large B-cell lymphoma.

John DiPersio, MD, PhD, and Michael Bishop, MD, review the use of JAK inhibitors in chronic GvHD and practical considerations for disease management.

Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, discuss and compare BTK inhibitors used as targeted therapy for B-cell malignancies, taking into account data from clinical trials and their personal experiences.

Mazyar Shadman, MD, MPH, and Brian T. Hill, MD, PhD, discuss the importance of CD19-targeted therapy as a promising option in the relapsed/refractory DLBCL setting.

Future implications for palliative therapy with selective immunomodulating microtubule binding agents as prevention against chemotherapy-induced neutropenia in high-risk patients with solid tumors.

Joel Neal, MD, PhD, and Alexander I. Spira, MD, PhD, FACP, talk about the role of EGFR, particularly exon 20 insertion, in NSCLC growth and progression, and review the mechanism of action and current safety and efficacy data from the mobocertinib trial.

Experts discuss the role of CD19 in the therapeutic landscape for patients with transplant-ineligible relapsed/refractory DLBCL.

A discussion ofJAK2-directed therapies, their roles in treatment, and the key clinical trials guiding their use in myeloproliferative neoplasms. Also discussed are some relevant data recently presented at ASCO.

Jason M. Melear, MD, and Ian W. Flinn, MD, PhD, discuss the role of PI3K inhibitors in the management of R/R follicular lymphoma and marginal zone lymphoma.

Experts discuss advances in gastrointestinal stromal tumors (GIST) and dive into the evolving landscape and ongoing unmet needs.

Experts in genitourinary oncology discuss emerging research surrounding the clinical utility of phenotypic biomarkers, such as prostate-specific membrane antigen (PSMA), for use in the treatment of metastatic castration-resistant prostate cancer.

A panel discusses the role of TKI combination therapies for patients with advanced renal cell carcinoma and how they have changed the treatment landscape.

A review of key relevant data on HER2-positive breast cancer from the 2020 SABCS Virtual Symposium.

Expert physicians discuss the rationale behind the clinical use of JAK inhibitors in acute GvHD (graft-versus-host disease), and provide an overview of recent clinical trial data for this treatment approach.

An in-depth discussion on the targeting of specific molecular pathways with newer, novel therapies to better manage patients with liver cancer.

Experts from Sarah Cannon Research Institute talk about the expanding role of targeted treatment options in early HER2+ breast cancer.

A discussion on a novel therapeutic target for treatment, known as exportin 1 (XPO1), and the first selective nuclear export inhibitor to enter clinical use for patients who have developed relapse after IMiD and protease inhibitor therapies.

Dr Mark Pegram and Dr Julie Gralow discuss treatment options in relapsed/refractory HER2+ metastatic breast cancer.

Key opinion leaders discuss the evolving treatment paradigm for relapsed/refractory gastrointestinal stromal tumors, and provide an overview of supplemental data presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting.

Shared insight on recent advances in KRAS-mutant NSCLC, with a focus on new therapies on the horizon.

Jennifer R. Brown, MD, PhD, and Alan Skarbnik, MD, describe the rationale for treating chronic lymphocytic leukemia with BTK inhibition, and explore current trends in data that impact treatment selection.